Climb Bio, a clinical-stage biotech, focuses on potentially best-in-class monoclonal antibodies for immune-mediated diseases, primarily through its lead candidate budoprutug targeting CD19-positive B cells. The company improved operating losses from $82 million in 2024 to $67.9 million in 2025, supported by over $160 million in cash and equivalents expected to fund operations into 2028. Budoprutug’s Phase 2 pMN trial and Phase 1b/2a ITP and SLE studies, alongside early trials of CLYM116 in IgAN, form key growth catalysts but remain subject to typical biotech clinical and regulatory risks. Climb Bio navigates a competitive landscape with established pharma players while managing high R&D expenses and complex regulatory environments.